Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.53 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 15/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5214862 | 0.84 | RPS6KA3 (0.70) | RPS6KA3ADORA1ADORA2APTGS2ADORA2B | |
| SCHEMBL28360587 | 0.82 | GAA (0.56) | ADORA1ADORA2A | |
| SCHEMBL31061144 | 0.79 | ADORA1 (0.55) | ADORA1ADORA2APTGS2ADORA2B | |
| SCHEMBL6133449 | 0.79 | ADORA1 (0.41) | NUDT1RPS6KA3ADORA1ADORA2ATDP1 | |
| SCHEMBL1350076 | 0.78 | AKT1 (0.45) | RPS6KA3ADORA1ADORA2A | |
| SCHEMBL6133483 | 0.78 | CYP1A2 (0.50) | NUDT1RPS6KA3ADORA1ADORA2APTGS2 | |
| SCHEMBL24309336 | 0.77 | ADORA1 (0.46) | ADORA1ADORA2APTGS2ADORA2B | |
| SCHEMBL18496447 | 0.77 | ACHE (0.53) | RPS6KA3ADORA1ADORA2APTGS2TDP1 | |
| SCHEMBL5451373 | 0.76 | ADORA1 (0.53) | RPS6KA3ADORA1ADORA2APTGS2ADORA2B | |
| SCHEMBL5451875 | 0.76 | ADORA1 (0.57) | ADORA1ADORA2APTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205302-B2 | Anticoagulants; antilipemic agents; cardiovascular disorders | NIPPON SHINYAKU CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
| EP-1400518-B1 | HETEROCYCLIC COMPOUND DERIVATIVES AND MEDICINES | NIPPON SHINYAKU CO LTD (JP) | 2007-01-17 | — | — | EP | disclosed |
| US-20040102436-A1 | Heterocyclic compound derivatives and medicines | NIPPON SHINYAKU CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1400518-A1 | HETEROCYCLIC COMPOUND DERIVATIVES AND MEDICINES | Nippon Shinyaku Co., Ltd. (JP) | 2004-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102436-A1 | Heterocyclic compound derivatives and medicines | CNR2, CNR1, GPR55 | NUDT1 2498/4885RPS6KA3 1852/4885ADORA1 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.